|
|
Post by lakers on Sept 29, 2016 1:20:46 GMT -5
|
|
|
|
Post by boytroy88 on Sept 29, 2016 10:36:28 GMT -5
Wow, that's an article from 2011.. |
|
|
|
Post by mnholdem on Sept 29, 2016 11:10:23 GMT -5
That 2nd CRL from the FDA cost this company much more than the additional cost to bring Afrezza to market. MannKind could have developed many API rather than being forced to table most of the pipeline. The pediatric trials for Afrezza would have been completely by now as well. Some have reported that the cost of that CRL, prompted by Martin Shkreli and focused on the inhalation device, came to over $300 million.
MannKind could have done a lot with $300 million. In fact, Epi-TS could have been on the market by now, in addition to Afrezza sales revenues that would have been pouring in by now. 
Still, if CEO Matt Pfeffer can work out a deal for a BP to develop Epi-TS, it would be the partner who would fund its development.  |
|
|
|
Post by centralcoastinvestor on Sept 29, 2016 14:34:39 GMT -5
That 2nd CRL from the FDA cost this company much more than the additional cost to bring Afrezza to market. MannKind could have developed many API rather than being forced to table most of the pipeline. The pediatric trials for Afrezza would have been completely by now as well. Some have reported that the cost of that CRL, prompted by Martin Shkreli and focused on the inhalation device, came to over $300 million.
MannKind could have done a lot with $300 million. In fact, Epi-TS could have been on the market by now, in addition to Afrezza sales revenues that would have been pouring in by now.
Still, if CEO Matt Pfeffer can work out a deal for a BP to develop Epi-TS, it would be the partner who would fund its development. It appears that anything that poisonous toad Shkreli touched was contaminated. To this day, I cannot understand why the FDA would have listened to that weasel. And how, after all of the revelations about his business dealings, the FDA would not have launched an internal investigation into that event. |
|
|
|
Post by audiomr on Sept 30, 2016 0:06:25 GMT -5
This appears to be a different mode of action from TS-epi. That is, it appears to be topical rather than systemic. TS-epi would go to the lungs, releasing the epinephrine into the bloodstream. The mist would seem to work by depositing epi in the trachea. Different treatments for different issues.
|
|
